Bank of Montreal Can reduced its holdings in  Seagen Inc. (NASDAQ:SGEN – Get Rating) by 36.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 58,999 shares of the biotechnology company’s stock after selling 33,664 shares during the quarter. Bank of Montreal Can’s holdings in Seagen were worth $7,796,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in SGEN. State of New Jersey Common Pension Fund D grew its stake in shares of  Seagen by 1.6% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 83,767 shares of the biotechnology company’s stock valued at $10,765,000 after buying an additional 1,308 shares during the period.  CWM LLC boosted its holdings in  Seagen by 185.1% in the fourth quarter. CWM LLC now owns 24,345 shares of the biotechnology company’s stock valued at $3,129,000 after acquiring an additional 15,807 shares during the last quarter.  DekaBank Deutsche Girozentrale grew its position in  Seagen by 8.7% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 174,527 shares of the biotechnology company’s stock valued at $21,941,000 after acquiring an additional 14,033 shares during the period.  Kestra Advisory Services LLC increased its stake in  Seagen by 67.6% during the fourth quarter. Kestra Advisory Services LLC now owns 9,559 shares of the biotechnology company’s stock worth $1,228,000 after acquiring an additional 3,856 shares during the last quarter.  Finally, Triumph Capital Management purchased a new position in shares of  Seagen in the 4th quarter worth about $854,000. 86.25% of the stock is owned by institutional investors and hedge funds.

Several equities analysts have recently weighed in on SGEN shares. Raymond James lowered Seagen from a “strong-buy” rating to a “market perform” rating in a research note on Monday, March 13th. Evercore ISI raised shares of Seagen from an “in-line” rating to an “outperform” rating and increased their price objective for the stock from $140.00 to $175.00 in a research report on Thursday, February 16th. SVB Securities raised their target price on shares of Seagen from $141.00 to $229.00 in a research note on Tuesday, March 14th. Royal Bank of Canada upped their price target on shares of Seagen from $155.00 to $229.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 14th. Finally, Truist Financial increased their price target on Seagen from $152.00 to $229.00 in a report on Monday, March 20th. Twelve research analysts have rated the stock with a hold rating and six have assigned  a buy rating to the company. According to MarketBeat.com, the stock  has a consensus rating of “Hold” and a consensus price target of $188.33.

In other news, CFO Todd E. Simpson sold 55,344 shares of the business’s stock in a transaction that occurred on Monday, April 10th. The stock was sold at an average price of $204.58, for a total value of $11,322,275.52. Following the completion of the sale, the chief financial officer now directly owns 118,946 shares in the company, valued at approximately $24,333,972.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CFO Todd E. Simpson sold 243 shares of the stock in a transaction dated Thursday, April 6th. The shares were sold at an average price of $205.86, for a total transaction of $50,023.98. Following the sale, the chief financial officer now owns 118,946 shares in the company, valued at $24,486,223.56. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Todd E. Simpson sold 55,344 shares of the firm’s stock in a transaction dated Monday, April 10th. The stock was sold at an average price of $204.58, for a total transaction of $11,322,275.52. Following the completion of the transaction, the chief financial officer now directly owns 118,946 shares in the company, valued at approximately $24,333,972.68. The disclosure for this sale can be found here. Over the last three months, insiders sold 210,568 shares of company stock worth $38,206,836. Corporate insiders own  27.30% of the company’s stock.

SGEN stock opened at $205.00 on Wednesday. The stock’s 50 day moving average is $183.86 and its two-hundred day moving average is $149.36. The company has a market capitalization of $38.29 billion, a PE ratio of -62.12 and a beta of 0.54. Seagen Inc. has a 52-week low of $105.43 and a 52-week high of $207.16.

Seagen (NASDAQ:SGEN – Get Rating) last posted its quarterly earnings data on Wednesday, February 15th. The biotechnology company reported ($0.80) EPS for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.22. The firm had revenue of $528.20 million for the quarter, compared to the consensus estimate of $479.81 million. Seagen had a negative net margin of 31.10% and a negative return on equity of 21.13%. The firm’s revenue was up 22.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.95) EPS.  As a group, sell-side analysts anticipate that  Seagen Inc. will post -2.98 EPS for the current year.

Seagen Inc is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also engages in the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B.

Want to see what other hedge funds are holding SGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Seagen Inc. (NASDAQ:SGEN – Get Rating).

Receive News & Ratings for Seagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seagen and related companies with MarketBeat.com's FREE daily email newsletter.